<p>在過去的 7 天裏，美國市場下跌了 2.5%，但在過去一年中上漲了 23%，預計未來幾年收益將以每年 17% 的速度增長。在這種波動的表現和預期增長的背景下，擁有高內部持股的股票可能會很有吸引力，因為它們通常表明公司運營最親近的人對公司及其潛在的可觀收益增長的信心。</p>
<h3>美國高內部持股的十大成長公司</h3>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名稱</strong></td>
<td><strong>內部持股</strong></td>
<td><strong>收益增長</strong></td>
</tr>
<tr>
<td>Uxin (UXIN)</td>
<td>34.3%</td>
<td>74.1%</td>
</tr>
<tr>
<td>Upstart Holdings (UPST)</td>
<td>14.1%</td>
<td>57.3%</td>
</tr>
<tr>
<td>On Holding (ONON)</td>
<td>26%</td>
<td>23.1%</td>
</tr>
<tr>
<td>KVH Industries (KVHI)</td>
<td>16.3%</td>
<td>146.1%</td>
</tr>
<tr>
<td>Karman Holdings (KRMN)</td>
<td>15.6%</td>
<td>52.6%</td>
</tr>
<tr>
<td>Duos Technologies Group (DUOT)</td>
<td>11.2%</td>
<td>158.4%</td>
</tr>
<tr>
<td>Corcept Therapeutics (CORT)</td>
<td>11.7%</td>
<td>48.9%</td>
</tr>
<tr>
<td>Astera Labs (ALAB)</td>
<td>10.3%</td>
<td>29.3%</td>
</tr>
<tr>
<td>AppLovin (APP)</td>
<td>27.4%</td>
<td>21.7%</td>
</tr>
<tr>
<td>Abeona Therapeutics (ABEO)</td>
<td>16.7%</td>
<td>32.9%</td>
</tr>
</tbody>
</table>
<p>點擊此處查看我們高內部持股的快速成長美國公司篩選器中的 176 只股票的完整列表。</p>
<p>在這裏，我們重點介紹我們獨家篩選器中的幾隻最愛。</p>
<h2>ImmunityBio (IBRX)</h2>
<p><strong>Simply Wall St 成長評級：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> ImmunityBio, Inc.是一家生物技術公司，致力於開發和商業化先進的免疫療法，旨在增強免疫系統對癌症和傳染病的反應，市值約為 72.5 億美元。</p>
<p><strong>運營：</strong> 該公司從其專注於開發下一代療法的部門產生了 1.4098 億美元的收入。</p>
<p><strong>內部持股：</strong> 28.2%</p>
<p><strong>收益增長預測：</strong> 每年 64.1%。</p>
<p>ImmunityBio 是一家以增長為導向的公司，內部持股顯著，正在推進其針對 BCG 無反應非肌肉侵襲性膀胱癌的 ANKTIVA 治療。最近 FDA 接受其補充生物製劑許可證申請，可能會擴大 ANKTIVA 的適應症。儘管預計年收入增長 47.8%，ImmunityBio 面臨財務挑戰，現金流不足一年，且最近出現股東稀釋。分析師一致認為股票價格有上漲潛力，儘管該公司目前的交易價格遠低於估計的公允價值。</p>
<ul>
<li>解鎖我們對 ImmunityBio 股票分析的全面見解，詳見本成長報告。</li>
<li>在審查我們最新的估值報告後，ImmunityBio 的股價可能過於悲觀。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/b2d6e0fd-dc1f-4014-8f92-60363368b53b/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1642" height="1048" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/b2d6e0fd-dc1f-4014-8f92-60363368b53b/chart/earnings-and-revenue-growth"/></p>
<p>截至 2026 年 6 月的 IBRX 收益和收入增長</p>
<h2>理想汽車 (LI)</h2>
<p><strong>Simply Wall St 成長評級：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> 理想汽車在中華人民共和國的能源汽車市場運營，市值約為 144.8 億美元。</p>
<p><strong>運營：</strong> 理想汽車主要通過其汽車製造部門產生收入，總計為 1093.7 億人民幣。</p>
<p><strong>內部持股：</strong> 33%</p>
<p><strong>收益增長預測：</strong> 每年 61.6%。</p>
<p>理想汽車以高內部持股為特徵，在挑戰中尋求增長。該公司預計年收入增長 13%，超過美國市場。然而，最近的收益顯示 2026 年第一季度淨虧損 22.9 億人民幣，儘管車輛交付量已超過 170 萬輛。理想汽車的戰略舉措包括 10 億美元的股票回購和推出新車型如理想 L9，以增強其在競爭激烈的電動車市場中的地位。</p>
<ul>
<li>在我們的收益增長報告中更深入地瞭解理想汽車的潛力。</li>
<li>我們精心準備的理想汽車估值報告表明，其股價可能過高。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/9eb69e11-e6b7-42a1-afa3-9f2354e8ac7f/chart/ownership-breakdown?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1642" height="540" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/9eb69e11-e6b7-42a1-afa3-9f2354e8ac7f/chart/ownership-breakdown"/></p>
<p>截至 2026 年 6 月的 LI 持股結構</p>
<h2>Ethos Technologies (LIFE)</h2>
<p><strong>Simply Wall St 成長評級：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> Ethos Technologies Inc.在美國作為保險政策的第三方管理者運營，市值約為 10.6 億美元。</p>
<p><strong>運營：</strong> 該公司主要通過其保險經紀服務產生收入，總計為 4.8582 億美元。</p>
<p><strong>內部持股：</strong> 22%</p>
<p><strong>收益增長預測：</strong> 每年 94.5%。</p>
<p>Ethos Technologies 擁有顯著的內部持股，通過戰略合作和技術進步擴展其數字人壽保險產品。與 Liberty Mutual 和 Banner Life Insurance 的近期合作增強了 Ethos 的市場覆蓋和產品組合。儘管 2026 年第一季度淨虧損為 1.6639 億美元，收入從去年激增至 1.931 億美元。推出 ChatGPT 應用程序標誌着他們在不斷發展的保險領域中對消費者參與的創新方法，儘管最近注意到內部人士的賣出。</p>
<ul>
<li>通過我們的全面分析師估計報告深入瞭解 Ethos Technologies。</li>
<li>在審查我們最新的估值報告後，Ethos Technologies 的股價可能過於樂觀。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/fbc02edd-aafc-4f38-aa18-ae0098f75905/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1642" height="1048" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/fbc02edd-aafc-4f38-aa18-ae0098f75905/chart/earnings-and-revenue-growth"/></p>
<p>截至 2026 年 6 月的 LIFE 收益和收入增長</p>
<h2>抓住機會</h2>
<ul>
<li>點擊此鏈接深入瞭解我們高內部持股的快速成長美國公司篩選器中的 176 家公司。</li>
<li>對其他選擇感到好奇？這項技術可能會取代計算機：發現 30 只股票正在努力使量子計算成為現實。</li>
</ul>
<p><em>這篇來自 Simply Wall St 的文章是一般性的。<strong>我們提供的評論基於歷史數據和分析師預測，僅使用無偏見的方法，我們的文章並不旨在提供財務建議。</strong> 它不構成買賣任何股票的推薦，也未考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。該分析僅考慮內部人士直接持有的股票，不包括通過其他工具（如公司和/或信託實體）間接持有的股票。所有預測的收入和收益增長率均以年化（每年）增長率的形式表示，時間範圍為 1-3 年。</em></p>
<h3>估值是複雜的，但我們在這裏為您簡化它。</h3>
<p>通過我們的詳細分析，發現 Ethos Technologies 是否被低估或高估，分析內容包括 <strong>公允價值估算、潛在風險、股息、內部交易及其財務狀況。</strong></p>
<p>獲取免費分析</p>

LIFE

IBRX

<p>這篇文章強調了美國一些高管持股比例較高的成長型公司，如 ImmunityBio、理想汽車和 Ethos Technologies，指出它們在盈利增長方面的潛力。文章概述了這些公司的運營情況、高管持股和財務預測，同時提醒讀者，內容是基於歷史數據的一般分析，並非財務建議</p>

<p>Over the last 7 days, the United States market has dropped by 2.5%, yet it has risen by 23% over the past year, with earnings expected to grow by 17% annually in the coming years. In this context of fluctuating performance and anticipated growth, stocks with high insider ownership can be appealing as they often signal confidence from those closest to the company's operations and potential for substantial earnings growth.</p>
<div class="lb-trans"><p>在過去的 7 天裏，美國市場下跌了 2.5%，但在過去一年中上漲了 23%，預計未來幾年收益將以每年 17% 的速度增長。在這種波動的表現和預期增長的背景下，擁有高內部持股的股票可能會很有吸引力，因為它們通常表明公司運營最親近的人對公司及其潛在的可觀收益增長的信心。</p>
</div><h3>Top 10 Growth Companies With High Insider Ownership In The United States</h3>
<div class="lb-trans"><h3>美國高內部持股的十大成長公司</h3>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Name</strong></td>
<td><strong>Insider Ownership</strong></td>
<td><strong>Earnings Growth</strong></td>
</tr>
<tr>
<td>Uxin (UXIN)</td>
<td>34.3%</td>
<td>74.1%</td>
</tr>
<tr>
<td>Upstart Holdings (UPST)</td>
<td>14.1%</td>
<td>57.3%</td>
</tr>
<tr>
<td>On Holding (ONON)</td>
<td>26%</td>
<td>23.1%</td>
</tr>
<tr>
<td>KVH Industries (KVHI)</td>
<td>16.3%</td>
<td>146.1%</td>
</tr>
<tr>
<td>Karman Holdings (KRMN)</td>
<td>15.6%</td>
<td>52.6%</td>
</tr>
<tr>
<td>Duos Technologies Group (DUOT)</td>
<td>11.2%</td>
<td>158.4%</td>
</tr>
<tr>
<td>Corcept Therapeutics (CORT)</td>
<td>11.7%</td>
<td>48.9%</td>
</tr>
<tr>
<td>Astera Labs (ALAB)</td>
<td>10.3%</td>
<td>29.3%</td>
</tr>
<tr>
<td>AppLovin (APP)</td>
<td>27.4%</td>
<td>21.7%</td>
</tr>
<tr>
<td>Abeona Therapeutics (ABEO)</td>
<td>16.7%</td>
<td>32.9%</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名稱</strong></td>
<td><strong>內部持股</strong></td>
<td><strong>收益增長</strong></td>
</tr>
<tr>
<td>Uxin (UXIN)</td>
<td>34.3%</td>
<td>74.1%</td>
</tr>
<tr>
<td>Upstart Holdings (UPST)</td>
<td>14.1%</td>
<td>57.3%</td>
</tr>
<tr>
<td>On Holding (ONON)</td>
<td>26%</td>
<td>23.1%</td>
</tr>
<tr>
<td>KVH Industries (KVHI)</td>
<td>16.3%</td>
<td>146.1%</td>
</tr>
<tr>
<td>Karman Holdings (KRMN)</td>
<td>15.6%</td>
<td>52.6%</td>
</tr>
<tr>
<td>Duos Technologies Group (DUOT)</td>
<td>11.2%</td>
<td>158.4%</td>
</tr>
<tr>
<td>Corcept Therapeutics (CORT)</td>
<td>11.7%</td>
<td>48.9%</td>
</tr>
<tr>
<td>Astera Labs (ALAB)</td>
<td>10.3%</td>
<td>29.3%</td>
</tr>
<tr>
<td>AppLovin (APP)</td>
<td>27.4%</td>
<td>21.7%</td>
</tr>
<tr>
<td>Abeona Therapeutics (ABEO)</td>
<td>16.7%</td>
<td>32.9%</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 176 stocks from our Fast Growing US Companies With High Insider Ownership screener.</p>
<div class="lb-trans"><p>點擊此處查看我們高內部持股的快速成長美國公司篩選器中的 176 只股票的完整列表。</p>
</div><p>Below we spotlight a couple of our favorites from our exclusive screener.</p>
<div class="lb-trans"><p>在這裏，我們重點介紹我們獨家篩選器中的幾隻最愛。</p>
</div><h2>ImmunityBio (IBRX)</h2>
<div class="lb-trans"><h2>ImmunityBio (IBRX)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 成長評級：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> ImmunityBio, Inc. is a biotechnology company dedicated to developing and commercializing advanced immunotherapies aimed at enhancing the immune system's response to cancer and infectious diseases, with a market cap of approximately $7.25 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> ImmunityBio, Inc.是一家生物技術公司，致力於開發和商業化先進的免疫療法，旨在增強免疫系統對癌症和傳染病的反應，市值約為 72.5 億美元。</p>
</div><p><strong>Operations:</strong> The company generates revenue of $140.98 million from its segment focused on developing next-generation therapies.</p>
<div class="lb-trans"><p><strong>運營：</strong> 該公司從其專注於開發下一代療法的部門產生了 1.4098 億美元的收入。</p>
</div><p><strong>Insider Ownership:</strong> 28.2%</p>
<div class="lb-trans"><p><strong>內部持股：</strong> 28.2%</p>
</div><p><strong>Earnings Growth Forecast:</strong> 64.1% p.a.</p>
<div class="lb-trans"><p><strong>收益增長預測：</strong> 每年 64.1%。</p>
</div><p>ImmunityBio, a growth-focused company with significant insider ownership, is advancing its ANKTIVA treatment for BCG-unresponsive non-muscle invasive bladder cancer. Recent FDA acceptance of its supplemental Biologics License Application could expand ANKTIVA's indications. Despite expected revenue growth of 47.8% annually, ImmunityBio faces financial challenges with less than a year of cash runway and recent shareholder dilution. Analysts agree on potential stock price appreciation, though the company currently trades significantly below estimated fair value.</p>
<div class="lb-trans"><p>ImmunityBio 是一家以增長為導向的公司，內部持股顯著，正在推進其針對 BCG 無反應非肌肉侵襲性膀胱癌的 ANKTIVA 治療。最近 FDA 接受其補充生物製劑許可證申請，可能會擴大 ANKTIVA 的適應症。儘管預計年收入增長 47.8%，ImmunityBio 面臨財務挑戰，現金流不足一年，且最近出現股東稀釋。分析師一致認為股票價格有上漲潛力，儘管該公司目前的交易價格遠低於估計的公允價值。</p>
</div><ul>
<li>Unlock comprehensive insights into our analysis of ImmunityBio stock in this growth report.</li>
<li>Upon reviewing our latest valuation report, ImmunityBio's share price might be too pessimistic.</li>
</ul>
<div class="lb-trans"><ul>
<li>解鎖我們對 ImmunityBio 股票分析的全面見解，詳見本成長報告。</li>
<li>在審查我們最新的估值報告後，ImmunityBio 的股價可能過於悲觀。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/b2d6e0fd-dc1f-4014-8f92-60363368b53b/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/b2d6e0fd-dc1f-4014-8f92-60363368b53b/chart/earnings-and-revenue-growth"/></p>
<p>IBRX Earnings and Revenue Growth as at Jun 2026</p>
<div class="lb-trans"><p>截至 2026 年 6 月的 IBRX 收益和收入增長</p>
</div><h2>Li Auto (LI)</h2>
<div class="lb-trans"><h2>理想汽車 (LI)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 成長評級：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> Li Auto Inc. operates in the energy vehicle market in the People’s Republic of China with a market cap of approximately $14.48 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 理想汽車在中華人民共和國的能源汽車市場運營，市值約為 144.8 億美元。</p>
</div><p><strong>Operations:</strong> Li Auto generates revenue primarily from its auto manufacturing segment, totaling CN¥109.37 billion.</p>
<div class="lb-trans"><p><strong>運營：</strong> 理想汽車主要通過其汽車製造部門產生收入，總計為 1093.7 億人民幣。</p>
</div><p><strong>Insider Ownership:</strong> 33%</p>
<div class="lb-trans"><p><strong>內部持股：</strong> 33%</p>
</div><p><strong>Earnings Growth Forecast:</strong> 61.6% p.a.</p>
<div class="lb-trans"><p><strong>收益增長預測：</strong> 每年 61.6%。</p>
</div><p>Li Auto, characterized by high insider ownership, is navigating growth amid challenges. The company forecasts a 13% annual revenue increase, outpacing the US market. However, recent earnings revealed a net loss of CNY 2.29 billion for Q1 2026 despite vehicle deliveries reaching over 1.7 million year-to-date. Li Auto's strategic moves include a US$1 billion share buyback and launching new models like the Li L9 to bolster its position in the competitive electric vehicle sector.</p>
<div class="lb-trans"><p>理想汽車以高內部持股為特徵，在挑戰中尋求增長。該公司預計年收入增長 13%，超過美國市場。然而，最近的收益顯示 2026 年第一季度淨虧損 22.9 億人民幣，儘管車輛交付量已超過 170 萬輛。理想汽車的戰略舉措包括 10 億美元的股票回購和推出新車型如理想 L9，以增強其在競爭激烈的電動車市場中的地位。</p>
</div><ul>
<li>Take a closer look at Li Auto's potential here in our earnings growth report.</li>
<li>Our expertly prepared valuation report Li Auto implies its share price may be too high.</li>
</ul>
<div class="lb-trans"><ul>
<li>在我們的收益增長報告中更深入地瞭解理想汽車的潛力。</li>
<li>我們精心準備的理想汽車估值報告表明，其股價可能過高。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/9eb69e11-e6b7-42a1-afa3-9f2354e8ac7f/chart/ownership-breakdown" alt="" original-src="https://images.simplywall.st/company/9eb69e11-e6b7-42a1-afa3-9f2354e8ac7f/chart/ownership-breakdown"/></p>
<p>LI Ownership Breakdown as at Jun 2026</p>
<div class="lb-trans"><p>截至 2026 年 6 月的 LI 持股結構</p>
</div><h2>Ethos Technologies (LIFE)</h2>
<div class="lb-trans"><h2>Ethos Technologies (LIFE)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 成長評級：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> Ethos Technologies Inc. operates as a third-party administrator for insurance policies in the United States and has a market cap of approximately $1.06 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> Ethos Technologies Inc.在美國作為保險政策的第三方管理者運營，市值約為 10.6 億美元。</p>
</div><p><strong>Operations:</strong> The company generates revenue primarily from its insurance broker services, amounting to $485.82 million.</p>
<div class="lb-trans"><p><strong>運營：</strong> 該公司主要通過其保險經紀服務產生收入，總計為 4.8582 億美元。</p>
</div><p><strong>Insider Ownership:</strong> 22%</p>
<div class="lb-trans"><p><strong>內部持股：</strong> 22%</p>
</div><p><strong>Earnings Growth Forecast:</strong> 94.5% p.a.</p>
<div class="lb-trans"><p><strong>收益增長預測：</strong> 每年 94.5%。</p>
</div><p>Ethos Technologies, with significant insider ownership, is expanding its digital life insurance offerings through strategic partnerships and technological advancements. Recent collaborations with Liberty Mutual and Banner Life Insurance enhance Ethos' reach and product portfolio. Despite a Q1 2026 net loss of US$166.39 million, revenue surged to US$193.1 million from the previous year. The launch of a ChatGPT app signifies their innovative approach to consumer engagement in the evolving insurance landscape, although insider selling has been noted recently.</p>
<div class="lb-trans"><p>Ethos Technologies 擁有顯著的內部持股，通過戰略合作和技術進步擴展其數字人壽保險產品。與 Liberty Mutual 和 Banner Life Insurance 的近期合作增強了 Ethos 的市場覆蓋和產品組合。儘管 2026 年第一季度淨虧損為 1.6639 億美元，收入從去年激增至 1.931 億美元。推出 ChatGPT 應用程序標誌着他們在不斷發展的保險領域中對消費者參與的創新方法，儘管最近注意到內部人士的賣出。</p>
</div><ul>
<li>Navigate through the intricacies of Ethos Technologies with our comprehensive analyst estimates report here.</li>
<li>Upon reviewing our latest valuation report, Ethos Technologies' share price might be too optimistic.</li>
</ul>
<div class="lb-trans"><ul>
<li>通過我們的全面分析師估計報告深入瞭解 Ethos Technologies。</li>
<li>在審查我們最新的估值報告後，Ethos Technologies 的股價可能過於樂觀。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/fbc02edd-aafc-4f38-aa18-ae0098f75905/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/fbc02edd-aafc-4f38-aa18-ae0098f75905/chart/earnings-and-revenue-growth"/></p>
<p>LIFE Earnings and Revenue Growth as at Jun 2026</p>
<div class="lb-trans"><p>截至 2026 年 6 月的 LIFE 收益和收入增長</p>
</div><h2>Seize The Opportunity</h2>
<div class="lb-trans"><h2>抓住機會</h2>
</div><ul>
<li>Click this link to deep-dive into the 176 companies within our Fast Growing US Companies With High Insider Ownership screener.</li>
<li>Curious About Other Options? This technology could replace computers: discover the 30 stocks are working to make quantum computing a reality.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊此鏈接深入瞭解我們高內部持股的快速成長美國公司篩選器中的 176 家公司。</li>
<li>對其他選擇感到好奇？這項技術可能會取代計算機：發現 30 只股票正在努力使量子計算成為現實。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.</em></p>
<div class="lb-trans"><p><em>這篇來自 Simply Wall St 的文章是一般性的。<strong>我們提供的評論基於歷史數據和分析師預測，僅使用無偏見的方法，我們的文章並不旨在提供財務建議。</strong> 它不構成買賣任何股票的推薦，也未考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。該分析僅考慮內部人士直接持有的股票，不包括通過其他工具（如公司和/或信託實體）間接持有的股票。所有預測的收入和收益增長率均以年化（每年）增長率的形式表示，時間範圍為 1-3 年。</em></p>
</div><h3>Valuation is complex, but we're here to simplify it.</h3>
<div class="lb-trans"><h3>估值是複雜的，但我們在這裏為您簡化它。</h3>
</div><p>Discover if Ethos Technologies might be undervalued or overvalued with our detailed analysis, featuring <strong>fair value estimates, potential risks, dividends, insider trades, and its financial condition.</strong></p>
<div class="lb-trans"><p>通過我們的詳細分析，發現 Ethos Technologies 是否被低估或高估，分析內容包括 <strong>公允價值估算、潛在風險、股息、內部交易及其財務狀況。</strong></p>
</div><p>Access Free Analysis</p>
<div class="lb-trans"><p>獲取免費分析</p>
</div>

三家內部人士持股比例高的成長型公司，盈利增長可達 94%